A Double-blind, Randomised, Placebo-controlled, Phase II Study to Evaluate ProCervix Efficacy to Clear HPV 16 and HPV 18 Infection in Women With Normal Cytology or ASCUS/LSIL

Trial Profile

A Double-blind, Randomised, Placebo-controlled, Phase II Study to Evaluate ProCervix Efficacy to Clear HPV 16 and HPV 18 Infection in Women With Normal Cytology or ASCUS/LSIL

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Mar 2017

At a glance

  • Drugs GTL 001 (Primary) ; Imiquimod
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Proof of concept; Therapeutic Use
  • Acronyms RHEIA-VAC
  • Sponsors GENTICEL
  • Most Recent Events

    • 13 Dec 2016 Results published in the Genticel Media Release
    • 01 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 25 Nov 2016 This Trial has been completed in Finland (end date: 2016-10-03) as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top